We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
An overview of the Program & LESI’s role/goals facilitating these conversations. This session discussed upcoming topics focused on what licensees need to know about SEP negotiations.
Litigation and enforcement actions; focus on what both sides need to know when negotiating SEPs.
This panel with dig into the various policy discussions around the Draft EU SEP regulations as well as US legislative proposals addressing SEPs – what is being proposed and what is the timeline, what is the appropriate role of government in these discussions.
An overview of the Program & LESI’s role/goals facilitating these conversations. This session will discuss topics that will be addressed in this track during the year related to AI in the Life Sciences industry — from specific uses such as drug discovery, clinical trials, medical devices to regulatory, IP and data related legal requirements and challenges.
Examples of who AI is used for drug discovery & clinical trials + IP regulatory challenges.
An overview of the Thought Leadership Program & LESI’s role/goals facilitating these conversations. In this first session, Sam Wiley of the LOT Network will interview Tillman Mueller-Stoy on his experience litigating the first case heard by the Unified Patent Court (UPC) and the considerations that went into his effective planning.
Examples of who AI is used for drug discovery & clinical trials + IP regulatory challenges.
These events are only open to current LES members. If you are not currently a member of a local LES Society, we encourage you to join your local LES society! If you are not ready to join LES, you can purchase a package for the LESI Thought Leadership Program (all three tracks) for $150 USD. Please contact the LESI Admin Office at NNE@lesi.org to register for this package.
